<SEC-DOCUMENT>0001070081-24-000021.txt : 20241107
<SEC-HEADER>0001070081-24-000021.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107161434
ACCESSION NUMBER:		0001070081-24-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		241435907

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20241107x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/7/2024 5:39:03 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 738555f3-a947-4e52-84ba-44a3c67cb44c -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20241107" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityCentralIndexKey" id="Tc_CEsvIoKCVEuiXTwz4LahHg_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:AmendmentFlag" id="Tc_HAyMpSKGCkWM-QUyJYmzqA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20241107.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-07</xbrli:startDate><xbrli:endDate>2024-11-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_96648a38_c0f7_4684_b696_b5d7445d59a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:DocumentType" id="Narr_CcDvzEWpzECbdYIpmUIEgw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_cix-aMqQ5UObILw180FpEw"><b style="font-size:9pt;font-weight:bold;">November&#160;7, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityRegistrantName" id="Narr_P6EdVc2ov0GZcKMEAJCFZA"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_vXLv_Mo0xESzC8Q3nNTJ6A_2_0"></a><a id="Tc_C8pjdq3HBEy0fHrZz8en0Q_2_2"></a><a id="Tc_sqUNV7tgiku5_OTl81KQDA_2_4"></a><a id="Tc_tnh8n-Zf00aeZ7WYfcgUXw_3_0"></a><a id="Tc_bKfN_SJr3USFpzbvHV32fQ_3_2"></a><a id="Tc_T7X9FATPuUCTsjEF8-rG-w_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_2h5KcqvGMUCoxAO0UGnZvw_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityFileNumber" id="Tc_DGxhU3nvMkigKMRck3irdA_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityTaxIdentificationNumber" id="Tc_xkJXBhWrwk-Enwn8wQ1feg_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_b4hXMIsZNUmq-90qTw4A1g_2_0"></a><a id="Tc_4UMVYteDW0iLe06B553WEQ_3_0"></a><a id="Tc_X_uFJ0ioUEqHkOxir8Z_xg_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityAddressAddressLine1" id="Tc_MNMmuChrM0qiyWgG14Pe9g_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityAddressCityOrTown" id="Narr_vbv8eigO90qW847TzB_G1A"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityAddressStateOrProvince" id="Narr_ocV0zIpRDEyI9qh0eT7_EA"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:EntityAddressPostalZipCode" id="Tc_cWad-95_nEuvLanz3EwrqQ_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:CityAreaCode" id="Narr_26Olhmm68kyITR4AM6ZsdQ"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:LocalPhoneNumber" id="Narr_uJC4yYiNe0ujqWuyOt62oA"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_ErTyQQKrbUuEbug8Tkg8QQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_XVlHEA--a0680v3WkV2MdA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_FoWDR15Xa0uefGXC8wAcww"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_dH3fyxliLUmlp4BEj7bftA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_1F0r1RrQ50ypZT989lDC6Q_1_0"></a><a id="Tc_TB7cUdPQP0KxhUWZJaCknw_1_2"></a><a id="Tc_F8mLzF7RME6P0qXa5xBe4w_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:Security12bTitle" id="Tc_Le3dj2-53UaxO5VjsekXjQ_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" name="dei:TradingSymbol" id="Tc_CeR6ISDBgk-56CjHz5d16Q_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_-9GiGX-n1EyKX3_9NeQUfg_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_32YRdx9fuEqH9YE1WILlmA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b3891bd9_2b5c_4007_8beb_ab1bff61963a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;2.02.&#160;Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On November&#160;7, 2024, <span style="color:#212529;background:#ffffff;">PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September&#160;30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K (this &#8220;Report&#8221;) and is incorporated by reference into this Item&#160;2.02.</span></p><a id="_ef00b37e_0b0d_46b9_95e8_1011d7b7e5f4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Company will host a conference call on November&#160;7, 2024, at 4:30&#160;PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September&#160;30, 2024, as well as other corporate highlights and updates. Directions on how to access the conference call are included in the press release furnished as Exhibit&#160;99.1 hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20241107xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated November&#160;7, 2024 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8cf83be_f354_496a_84d0_eb6891fd4fb5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;7, 2024</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20241107xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/7/2024 05:39:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports Third Quarter 2024 Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million &#8211; </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Regulatory filings for sepiapterin, Translarna&#8482; and AADC gene therapy under review by FDA &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; On track to achieve remaining 2024 clinical and regulatory milestones, </i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">including NDA submission for vatiquinone &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">WARREN, N.J., November 7, 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2024.&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&quot;I am proud of our team&#8217;s strong execution,&quot; said Matthew Klein, M.D., Chief Executive Officer. &#8220;</font><font style="font-family:'Arial','Helvetica','sans-serif';">We continue to achieve excellent revenue performance allowing us to raise full-year revenue guidance. In addition, we have submitted three approval applications to FDA so far this year, all of which have been accepted for review, and plan a fourth submission for vatiquinone for Friedreich ataxia in December. </font><font style="font-family:'Arial','Helvetica','sans-serif';">We are on our way to accomplishing all of our 2024 objectives and are in a strong financial position to execute on our long-term strategic plans.&#8221;&#160;&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Third quarter 2024 total revenue of $197 million</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Third quarter 2024 revenue for the DMD franchise was $124 million</font></td></tr></table><div style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Translarna&#8482; (ataluren) net product revenue was $72 million, driven by</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> continued access for patients in existing geographies, continued geographic expansion, high compliance and adherence, and dose adjustments.</font></div><div style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) net product revenue was $52 million, driven by new patient start</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">s, continued brand loyalty, high compliance and adherence, and dose adjustments.</font></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Milestones:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">PTC submitted an NDA to the FDA for sepiapterin for the treatment of PKU. The file was accepted for review, and the regulatory action date is set for July 29, 2025.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC resubmitted the NDA for Translarna for the treatment of nmDMD; the file was accepted, and a regulatory action date was not provided. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The BLA for PTC&#8217;s gene therapy for AADC deficiency remains on schedule for a regulatory action date of November 13, 2024.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC received Fast Track Designation for the PTC518 Huntington&#8217;s disease program.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to share topline data for the CardinALS trial of utreloxastat for the treatment of ALS in the fourth quarter of 2024. </font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Third Quarter 2024 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenues were $196.8 million for the third quarter of 2024, compared to $196.6 million for the third quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenue includes net product revenue across the commercial portfolio of $135.4 million for the third quarter of 2024, compared to $144.0 million for the third quarter of 2023. Total revenue also includes royalty and manufacturing revenue of $61.4 million in the third quarter of 2024, compared to $52.5 million for the third quarter of 2023. </font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna net product revenues were $72.3 million for the third quarter of 2024, compared to $69.0 million for the third quarter of 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Emflaza net product revenues were $51.9 million for the third quarter of 2024, compared to $67.4 million for the third quarter of 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2024 year-to-date sales of approximately CHF 1.2 billion, resulting in royalty revenue of $61.4 million to PTC for the third quarter of 2024, compared to $50.2 million for the third quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expenses were $161.4 million for the third quarter of 2024, compared to $164.2 million for the third quarter of 2023. The decrease in research and development expenses reflects strategic portfolio prioritization, as PTC continues to focus its resources on its differentiated, high-potential R&amp;D programs. Included in third quarter 2024 R&amp;D expense is $50.0 million in regulatory success-based milestones related to the Censa acquisition.&#160;&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expenses were $152.0 million for the third quarter of 2024, excluding $9.4 million in non-cash, stock-based compensation expense, compared to $150.2 million for the third quarter of 2023, excluding $14.0 million in non-cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expenses were $73.5 million for the third quarter of 2024, compared to $80.9 million for the third quarter of 2023. The decrease in selling, general and administrative expenses reflects lower employee costs as a result of the reduction in workforce in 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expenses were $63.1 million for the third quarter of 2024, excluding $10.3 million in non-cash, stock-based compensation expense, compared to $67.9 million for the third quarter of 2023, excluding $13.0 million in non-cash, stock-based compensation expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in the fair value of deferred and contingent consideration was a loss of $0.7 million for the third quarter of 2024, compared to a loss of $1.5 million for the third quarter of 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tangible asset impairment and losses (gains) on transactions, net, was a loss of $1.8 million for the third quarter of 2024, compared to $0.0 million for the third quarter of 2023. These results were primarily related to fixed asset impairments.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net loss was $106.7 million for the third quarter of 2024, compared to net loss of $133.0 million for the third quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities was $1,013.4 million on September 30, 2024, compared to $876.7 million on December 31, 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of September 30, 2024, were 76,952,124.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Updates Full Year 2024 Financial Guidance:&#160;</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates total revenues for full year 2024 to be between $750 million and $800 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $740 million and $835 million, including expected R&amp;D expense milestone payments of up to $65 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates non-GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $660 million and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expenses. As of September 30, 2024, $85 million in milestones have been achieved, of which $65 million has been recorded as R&amp;D operating expenses and $20 million as contingent consideration payable.&#160;&#160;&#160;</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:&#160;</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consolidated Statements of Operations&#160;</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">(In thousands, except share and per share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:24.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Three Months Ended September 30,&#8239;</b></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:middle;width:26.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Nine Months Ended September 30,</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2023</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Revenues:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net product revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;135,421&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;144,038&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;446,245&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;506,187&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Collaboration revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;6&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Royalty revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;61,365&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;50,173&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;145,702&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;117,857&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Manufacturing revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;2,365&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,661&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;6,716&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total revenues&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">196,786&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;196,576&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">593,608&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;630,766&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Operating expenses:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Cost of product sales, excluding amortization of acquired intangible assets&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;10,848&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;9,493&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;41,115&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;36,368&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Amortization of acquired intangible asset&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;3,036&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;58,649&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;57,431&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;145,461&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Research and development (1)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;161,412&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;164,212&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;409,710&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;545,210&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Selling, general and administrative (2)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;73,456&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80,886&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;216,228&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;256,249&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Change in the fair value of deferred and contingent consideration&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;700&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,500&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;5,700&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(125,000)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Intangible asset impairment&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;217,800&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Tangible asset impairment and losses (gains) on transactions, net&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,844&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;3,605&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total operating expenses&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">251,296&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;314,740&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">733,789&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,076,088&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Loss from operations&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(54,510)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(118,164)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(140,181)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(445,322)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Interest expense, net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(41,609)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(28,160)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(125,933)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(84,905)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Other expense, net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(1,872)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(20,266)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(2,306)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(8,832)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Loss before income tax (expense) benefit&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(97,991)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(166,590)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(268,420)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(539,059)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Income tax (expense) benefit&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(8,663)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;33,620&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(28,989)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;68,247&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net loss attributable to common stockholders&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(106,654)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(132,970)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(297,409)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(470,812)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Weighted-average shares outstanding:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Basic and diluted (in shares)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">76,925,523&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;75,377,997&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">76,716,340&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;74,618,611&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net loss per share&#8212;basic and diluted (in dollars per share)&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(1.39)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(1.76)&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(3.88)&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(6.31)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(1) Research and development reconciliation&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP research and development&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;161,412&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;164,212&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;409,710&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;545,210&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;9,416&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;13,986&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;27,810&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;44,828&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP research and development&#160;</b></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;151,996&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;150,226&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;381,900&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;500,382&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(2) Selling, general and administrative reconciliation&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP selling, general and administrative&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;73,456&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80,886&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;216,228&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;256,249&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;10,339&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;12,956&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;29,566&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;40,300&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:48.13%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP selling, general and administrative&#160;&#160;</b></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;63,117&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;67,930&#160;</font></p></td><td style="vertical-align:middle;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:11.48%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;186,662&#160;</font></p></td><td style="vertical-align:middle;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.78%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.34%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;215,949&#160;</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Summary Consolidated Balance Sheets&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">(in thousands, except share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:104.8%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:21.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">September 30, 2024</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:19.77%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">December 31, 2023</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Cash, cash equivalents and marketable securities&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,013,357&#160;</font></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;876,739&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total assets&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,842,236&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,895,698&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total debt&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;285,106&#160;</font></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;284,213&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total deferred revenue&#160;</font></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;801&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total liability for sale of future royalties&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;2,082,051&#160;</font></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,814,097&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total liabilities&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160; 2,896,588&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;2,714,253&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total stockholders&#39; deficit (76,952,124 and 75,708,889 common shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively)&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(1,054,352)&#160;</font></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(818,555)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:16.88%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1,842,236&#160;</b></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.98%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$&#160;</b></p></td><td style="vertical-align:middle;width:14.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,895,698&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:bottom;width:57.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP Milestone Payments Full Year 2024</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.3%;"><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Full Year 2024</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.96%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP R&amp;D Expense Related Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;65&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP Contingent Consideration Payable Related Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.93%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:12.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;25&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:86.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total Projected GAAP Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;90&#160;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&amp;D and SG&amp;A Expense&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80.76%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Low End of Range</b></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:middle;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">High End of Range</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP R&amp;D and SG&amp;A Expense&#160;</font></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;740&#160;</font></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;835&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: projected non-cash, stock-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80&#160;</font></p></td><td style="vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="3" style="vertical-align:middle;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected non-GAAP R&amp;D and SG&amp;A expense&#160;&#160;</font></p></td><td style="vertical-align:middle;width:2.2%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.35%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;660&#160;</font></p></td><td style="vertical-align:middle;width:1.33%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:2.38%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.04%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;755&#160;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">AADC: Aromatic l-Amino Acid Decarboxylase</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">ALS: Amyotrophic Lateral Sclerosis</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BLA: Biologics License Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FA: Friedreich Ataxia</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">nmDMD: Nonsense Mutation Duchenne Muscular Dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General, and Administrative</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';">click here</font><font style="font-family:'Arial','Helvetica','sans-serif';"> to register and yo</font><font style="font-family:'Arial','Helvetica','sans-serif';">u will b</font><font style="font-family:'Arial','Helvetica','sans-serif';">e provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> and follow us on Facebook, X, and LinkedIn.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Ellen Cavaleri</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (615) 618-6228</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">ecavaleri@ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Updates Full Year 2024 Financial Guidance&quot;, including with respect to (i) 2024 total revenue guidance, (ii) 2024 </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Commission adopts the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization for Translarna in the EEA, or PTC&#8217;s ability to identify other potential mechanisms by which it may provide Translarna to nmDMD patients in the EEA; PTC&#39;s ability to use the clinical data from its international drug registry study and real-world evidence concerning Translarna&#39;s benefits to support a continued marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC&#39;s ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from its trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to sepiapterin, including any regulatory submissions and potential approvals, commercialization, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under PTC&#8217;s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC&#39;s preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC&#39;s strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi, Waylivra or sepiapterin.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20241107.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/7/2024 5:39:10 PM-->
<!--Modified on: 11/7/2024 5:39:10 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20241107" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20241107" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241107_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>tmb-20241107_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/7/2024 5:39:10 PM-->
<!--Modified on: 11/7/2024 5:39:10 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20241107.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tmb-20241107_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/7/2024 5:39:10 PM-->
<!--Modified on: 11/7/2024 5:39:10 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>tmb-20241107_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/7/2024 5:39:10 PM-->
<!--Modified on: 11/7/2024 5:39:10 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20241107.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638665979499667535" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638665979499667535" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638665979499667535" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638665979499667535" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638665979499667535" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638665979499667535" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638665979499667535" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638665979499667535" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638665979499667535" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638665979499667535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638665979499667535" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638665979499677511" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638665979499677511" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638665979499677511" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638665979499677511" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638665979499677511" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638665979499677511" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638665979499677511" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638665979499677511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638665979499677511" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638665979499687513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638665979499687513" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638665979499687513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638665979499687513" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638665979499687513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638665979499687513" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638665979499687513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638665979499687513" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45169917672672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
M[3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]
M9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIX
MT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T
M_C6"R0_L?@!02P,$%     @ T(%G61PX9>H_ 0  / (   \   !X;"]W;W)K
M8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*^Y)UB,4^(J\#+5]?
M)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9OTDUL(,BDBN0-2TN'
M+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)W
MH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L
M]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6VP7#H:,1%=F6CSV&L
M0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3K'H,+"&I=1BH9+=S
M*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!
ML/?P&HT=S8\?M_P!4$L#!!0    ( -"!9UDD'INBK0   /@!   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN
M$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NT
MBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \P
MO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y
M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #0@6=999!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ T(%G69E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #0@6=90N]4>5D$  "_$   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ T(%G69^@&_"Q @
MX@P   T              ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #0@6=9EXJ[',     3 @  "P              @ %X#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #0@6=9'#AEZC\!   \ @  #P              @ %A
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T(%G620>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ T(%G6660>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20241107x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20241107.xsd</File>
    <File>tmb-20241107_def.xml</File>
    <File>tmb-20241107_lab.xml</File>
    <File>tmb-20241107_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20241107x8k.htm">tmb-20241107x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20241107x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20241107",
   "dts": {
    "schema": {
     "local": [
      "tmb-20241107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20241107_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20241107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20241107_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20241107x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20241107x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20241107x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001070081-24-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-24-000021-xbrl.zip
M4$L#!!0    ( -"!9UGQ,S]YSP,  %X/   0    =&UB+3(P,C0Q,3 W+GAS
M9-U738_;-A"]!^A_8'S7EYU-8F/703:;  %VVV*3 'L+*(JVB4JD0E*Q]]]W
M2)&R)4NRC;1 T9-ESILW;V;(H73];E?DZ">5B@E^,TG">((H)R)C?'TSJ?0J
M>#MYM_SMQ?7+('BZ?;Q'F2!50;E&1%*L:8:V3&_05U&6F*,'*B7+<W0K6;:F
M""5Q^#:,P_D5"H*EY;C%"GP$1Y9L&B;>\,'1";Y 21*]B:;Q]!6Z6LSFBR1&
M?SYXW -(6[%3P)W*%HIL:(&1QG)-]>^XH*K$A-Y,-EJ7BRC:;K=AJ4G*1$A$
M85F2)'XS05AKR=)*TT]"%G=TA:M<0RGXCPKG-C14**>F!BW @1E*RM4"-+2"
M;6>AD&L(%"?1T\/]%RO/@S/*&O NE7FH* G7XF<$!JO- RL5K#$N&_ *J]3R
M.D,+K*0.]'-)U3&\,779I<C[\-[2@DNZ:J5HE;LD7T=@;6H!ADRW,W2XJZ@V
M>BBII(0=^-Q?#F]MR=CE@RIFT=,]XW]Y),>,J'YF:SJJWD U&E/+@8B*:SFD
MO#:VRZWEH/)Y!-8#*;TB6FPY)#I2"&-.X?AY.-V13;]48^D4N$OM-G,RG\\C
M:VV4,M)/"H;N5AO8FM[2@G.Z-O-AI%RF'Y&#-6IT*0?D@*45X(QC[\\U.WVN
M \:5QIS0PQ/ 1KK3Q<-HTJ=GE>LDKXIIW^&:QM!+3;EB:4X# Z,2:YCT*IB:
M2>]FCY:=5K3D@3DR9L,W#>)9,$OV4ZN4E)S3ESURWU!]NIGZ0.,(.MN?%#M,
M6.^D>5U/&M89I0%-A\>I,=;;9/D"(7NO8,Z%ME4T2WZQ+!E?B7H%ULR16)@D
MOD+ED'GX]OAYJ)\VV3MWL?K?]SS[R#73SY^!5Q8VX 0QJ/192*_$:\GHBG%F
M5<=0LA@%R/L?/F*>H9H,';!=1UV.#GL%M_H??&F?H=$*J*RCF;W.V4%&' G.
M295?[K>7->CF%GU#?J5-3)%<J$K2+W!>,RPS*/^'2FE1O-\Q=2<*S+@;'\KU
MZR*7D<;!L(UMXQI"^.,Y$9"BFA496E3S(D_\_^ZAO]P>Z0K9^VAA1M;-1+&B
MS,U0M6L;^\*BBS3P(_0[9!K"./ (PSXRI>T6Z!;'Q?446)(CEJ/K$DA$2:5F
M<,WM+^;H'TH*JGEI4NT&_/=2RG%Z:4K@0O-_)9OKJ#/SW4+K9K#W J0EI$:\
M]_-CZ V@_G*Y%\1RC;B8?\V;1F"6@F0*]W,(H9W8<17]+^)GQO<.)O#592&/
MOV[Z8JHAN'FP6^/LJ*??:(8$G/*T_U4CI-X)-=GR;U!+ P04    " #0@6=9
M*V\H_^ "  #V"@  %    '1M8BTR,#(T,3$P-U]D968N>&ULM59;3]LP%'Y'
MVG_PPK/CN%T%C6A1H7N8U$H3,(DWE,:GK37'CFR'EG\_.TU"2@MT4%X27XZ_
MR_'UXG*="?0(VG E!P$-HP"!3!7C<C$("CO'Y\'E\-O)Q7>,[Z]N)HBIM,A
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M]=?A?<$4BNFAP(_&3IO5YIH_EWD 1,9"?13^G%Z0H(9M]B3"5 6G(?;Q<>W
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M;(LNRH$DT'H@2Y0'Z79)$E(\@L6 OH/XZD(C"T00&>!$)G#D4 5&T"<Z3''
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M3>?F]SS;G)^:/\J]S^N>.80_[;#C[/P_4$L#!!0    ( -"!9UEA=)EV,BX
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MLTX<4O@M/$YE,GY,5.//;R5G@638-$WH%T[1_'W-?,U,=;(;PE/)"/2/0'D
MYM?D]\4$)J_&2-ULAOA[K4#%X _F(Q"4GA!^SG%*&;!FLB&/!&"3!FY%1R&\
M60,),<&O0*J,N*\IH^H:4]YE63Y\:RFQ,]G^;S9=\K+5Q3X<3B1*0@<AH$](
ML'#_^<)]09!WLDA4\;.*J9__G'5OOJCY(@QIK-A%_H_+Y]L$N6YV9X8GAK7P
M1SW*6DBG(DTNAOP+"\J!+C.6?"$2<)238">AHWLFD9AAMO : S"D2^#;A-60
M*NPB$@^@'_/AH%V142\;SX]_ZW>Z?:!Y$I3'-?_2/JS\""5>.(>P[-&+5[=S
M"E<S:"(2K9F-^ /6_<'K=W-WN$ ,3N(<*7RNE\3BQ^(GPT^.G-RF>_W^-1F"
M?PU*&13L U4 *'CMJX JA8MW"@7MPS8:]?8R.N:#\;@$>J4X>/U1<E'33Q9H
M'' %FF=ZP2,]@D$H_+MYZ%Z#QN) '$#+$I4GT'EIP<N]Z1C^,CQ>O!);Z^V%
M0< J+H4_SL!@"%/)HI<D8@G:@T'JS^PHO8K=1KZ(#@DD:/2(#*:['UQAV@7:
M+%+&6XC!U@$R*30>V!>N=)AOQ,0(B 36'W@HL\^*QSZ\&F.6"(<\!JP08ZD8
M>Q"MD0"<'*:CA_AC( "Q-$ ]C^DN52_0NIC0L C=+T+?3(8A_8OF#:MTC0VW
M<;M=3=U%N2QB8R%U6R!GH9.=XO@L8'H2X!,GC[!5>Q5;P>L/.>9A."!N=T_C
M.9X92&2 4$QIF$QWP2P'&"LZ[="0=A_*T<I2(/Q]$:T\4G_B*098PUJ*W]U2
M+ \_EJR6:0J,*\XB*#32 6CP]]%NQ(#)0J)F%B?$$A)=@0+^R<=_?ZYC=!+3
M.T:&K@V?X+>EH#WU=8!!!R:Y@IX2_<6_TG!*&GT=:VS7";%.CX5RV>E!U&+D
M>A;Y8QJXB)V9*;T:K-$$_*%+_7P)K@:C=!U"\=5(:*L!2S""^G<#II6^QP79
M-=(79>;/[PQN =-%C'\NY8V_U(EPL%ZY#_:G/\URH@K#L<H?LR -C;N_%KH
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M              "  0\'  !T;6(M,C R-#$Q,#=?;&%B+GAM;%!+ 0(4 Q0
M   ( -"!9UF'\6UW<00  +<E   4              "  ?,,  !T;6(M,C R
M-#$Q,#=?<')E+GAM;%!+ 0(4 Q0    ( -"!9UEQFUFVOQ8  &"O   3
M          "  981  !T;6(M,C R-#$Q,#=X.&LN:'1M4$L! A0#%     @
MT(%G66%TF78R+@  8)P" !<              ( !AB@  '1M8BTR,#(T,3$P
B-WAE>#DY9#$N:'1M4$L%!@     &  8 B@$  .U6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tmb-20241107x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20241107.xsd" xlink:type="simple"/>
    <context id="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_CEsvIoKCVEuiXTwz4LahHg_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_HAyMpSKGCkWM-QUyJYmzqA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_CcDvzEWpzECbdYIpmUIEgw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_cix-aMqQ5UObILw180FpEw">2024-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_P6EdVc2ov0GZcKMEAJCFZA">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_2h5KcqvGMUCoxAO0UGnZvw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_DGxhU3nvMkigKMRck3irdA_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_xkJXBhWrwk-Enwn8wQ1feg_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_MNMmuChrM0qiyWgG14Pe9g_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_vbv8eigO90qW847TzB_G1A">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_ocV0zIpRDEyI9qh0eT7_EA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_cWad-95_nEuvLanz3EwrqQ_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_26Olhmm68kyITR4AM6ZsdQ">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_uJC4yYiNe0ujqWuyOt62oA">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_ErTyQQKrbUuEbug8Tkg8QQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_XVlHEA--a0680v3WkV2MdA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_FoWDR15Xa0uefGXC8wAcww">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_dH3fyxliLUmlp4BEj7bftA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_Le3dj2-53UaxO5VjsekXjQ_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_CeR6ISDBgk-56CjHz5d16Q_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Tc_-9GiGX-n1EyKX3_9NeQUfg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg"
      id="Narr_32YRdx9fuEqH9YE1WILlmA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
